Abstract: (1192 Views)
Aims: Diabetes has been known as a prevalence disorder and the use of common drugs has been faced many issues with multiple limitations. This study aimed to evaluate the use of carvacrol, as a novel agent, for treatment of diabetes.
Materials & Methods: In this experimental study, a single dose of streptozotocin (55mg/kg body weight) was used to induce the diabetes in rats. The animals were devided into 5 groups; healthy (negative control), diabetic (positive control), and diabetic given carvacrol in 5-, 10- and 15mg/kg body weight/day of carvacrol in neutral sterile olive oil solution. The levels of malondialdehyde, catalase, superoxide dismutase, and glutathione peroxidase (GPX) activities were evaluated. The levels of IL-1β, IL-6 and TNF-α expression in liver were assessed.
Findings: Streptozotocin increased the levels of malondialdehyde, IL-1β, IL-6 and TNF-α and also decreased activities of catalase, superoxide dismutase and glutathione peroxidase (p<0.05). Oral administration of carvacrol, especially 15mg/kg body weight/day, decreased the levels of malondialdehyde, IL-1β, IL-6 and TNF-α and also increased activities of catalase, superoxide dismutase and glutathione peroxidase in comparison to diabetic control (p<0.05).
Conclusion: Carvacrol decrease the negative effects of diabetes on inflammation and antioxidant status.
| |
Full-Text (HTML) (238 Views)